The company is not offering or selling any shares under this prospectus, and will not receive any of the proceeds from the sale of the shares by the selling stockholders pursuant to this prospectus.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics Appoints Steven Romano to Board
- Dianthus price target lowered to $36 from $38 at Wedbush
- Dianthus reports Q2 EPS (51c), consensus (55c)